Pre-Market Technical Recap on Biotech Stocks -- Array BioPharma, Catabasis Pharma, Cerulean Pharma, and Immunomedics

NEW YORK, June 21, 2017 /PRNewswire/ --

If you want a stock review on ARRY, CATB, CERU, or IMMU then come over to http://dailystocktracker.com/register/ and sign up for your free customized reports today. DailyStockTracker.com has initiated coverage on the following Biotech stocks: Array BioPharma Inc. (NASDAQ: ARRY), Catabasis Pharmaceuticals Inc. (NASDAQ: CATB), Cerulean Pharma Inc. (NASDAQ: CERU), and Immunomedics Inc. (NASDAQ: IMMU). According to a report released by professional services firm EY on Monday, June 19^th, 2017, revenue for American and European biotech companies reached $139.4 billion in 2016, up 7% from a year earlier. However, net income dropped 52% to $7.9 billion, and financing dropped 27% to $7.9 billion. Daily Stock Tracker provides great insights on these stocks in its free research reports at:

http://dailystocktracker.com/register/

Array BioPharma 

Boulder, Colorado headquartered Array BioPharma Inc.'s shares surged 8.02%, finishing Tuesday's trading session at $8.35. A total volume of 4.17 million shares was traded, which was higher than their three months average volume of 3.84 million shares. In the last month, the stock has advanced 1.33%. The Company's shares are trading above their 50-day and 200-day moving averages by 3.73% and 1.21%, respectively. Moreover, shares of Array BioPharma, which focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and Asia/Pacific, have a Relative Strength Index (RSI) of 57.21.

On May 30^th, 2017, Array BioPharma and Bristol-Myers Squibb Company announced that they have entered into a clinical research collaboration to investigate the safety, tolerability, and efficacy of the former's investigational MEK inhibitor, binimetinib, in combination with Bristol-Myers Squibb's Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment for metastatic colorectal cancer in patients with microsatellite stable tumors. Free research report on ARRY is available at:

http://dailystocktracker.com/registration/?symbol=ARRY

Catabasis Pharma 

On Tuesday, shares in Cambridge, Massachusetts-based Catabasis Pharmaceuticals Inc. recorded a trading volume of 90,095 shares, and ended the session 0.76% higher at $1.33. The stock is trading 4.12% below its 50-day moving average. Shares of the Company, which focuses on the discovery, development, and commercialization of therapeutic products based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the US, have an RSI of 44.54.

On June 08^th, 2017, Catabasis Pharma announced positive preclinical data on CAT-5571, supporting its potential as an oral treatment for cystic fibrosis (CF). These data, demonstrating CAT-5571's ability to significantly reduce the intracellular bacterial load of P. aeruginosa and B. cenocepacia, suggest that it could play an important role in improving clinical outcomes in combination with current CF therapies. The complimentary research report on CATB can be downloaded at:

http://dailystocktracker.com/registration/?symbol=CATB

Cerulean Pharma 

Shares in Waltham, Massachusetts headquartered Cerulean Pharma Inc. closed at $0.39, up 14.68% from the last trading session. The stock recorded a trading volume of 2.42 million shares, which was above its three months average volume of 1.77 million shares. The Company's shares are trading 18.78% below their 50-day moving average. Additionally, shares of Cerulean Pharma, which develops nanotechnology-based therapeutics in the areas of oncology and other diseases in the US, have an RSI of 44.54. Visit DailyStockTracker.com today and access our complete research report on CERU at:

http://dailystocktracker.com/registration/?symbol=CERU

Immunomedics 

Morris Plains, New Jersey headquartered Immunomedics Inc.'s stock ended 6.57% higher at $8.27. A total volume of 4.58 million shares was traded, which was above their three months average volume of 2.87 million shares. The Company's shares have advanced 12.52% in the last one month, 30.24% over the previous three months, and 125.34% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 21.53% and 77.92%, respectively. Furthermore, shares of Immunomedics, which focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases, have an RSI of 64.51. Free research report on IMMU is available at:

http://dailystocktracker.com/registration/?symbol=IMMU  

--

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@dailystocktracker.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://dailystocktracker.com/disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@dailystocktracker.com
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA